Novel Drugs and Biologics of 2016: A Boom for Neurodrugs in the Pipelin

DOI:

https://doi.org/10.37285/ijpsn.2017.10.5.1

Authors

  • D Samba Reddy

Abstract

This article provides a brief overview of novel drugs approved by the U.S. FDA in 2016.  It also focuses on the emerging boom in the development of neurodrugs for central nervous system (CNS) disorders. These new drugs are innovative products that often help advance clinical care worldwide, and in 2016, twenty-two such drugs were approved by the FDA. The list includes the first new drug for disorders such as spinal muscular atrophy, Duchenne muscular dystrophy or hallucinations and delusions of Parkinson’s disease, among several others. Notably, nine of twenty-two (40%) were novel CNS drugs, indicating the industry shifting to neurodrugs. Neurodrugs are the top selling pharmaceuticals worldwide, especially in America and Europe. Therapeutic neurodrugs have proven their significance many times in the past few decades, and the CNS drug portfolio represents some of the most valuable agents in the current pipeline. Many neuroproducts are vital or essential medicines in the current therapeutic armamentarium, including dozens of “blockbuster drugs” (drugs with $1 billion sales potential).  These drugs include antidepressants, antimigraine medications, and anti-epilepsy medications. The rise in neurodrugs’ sales is predominantly due to increased diagnoses of CNS conditions. The boom for neuromedicines is evident from the recent rise in investment, production, and introduction of new CNS drugs.  There are many promising neurodrugs still in the pipeline, which are developed based on the validated “mechanism-based” strategy. Overall, disease-modifying neurodrugs that can prevent or cure serious diseases, such as multiple sclerosis, epilepsy, and Alzheimer’s disease, are in high demand. 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Novel drugs, NCEs, First-in-class, CNS drugs, Blockbuster drugs, Neurodrugs

Downloads

Published

2017-09-30

How to Cite

1.
Reddy DS. Novel Drugs and Biologics of 2016: A Boom for Neurodrugs in the Pipelin. Scopus Indexed [Internet]. 2017 Sep. 30 [cited 2024 Jun. 14];10(5):3809-14. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/859

References

FDA (2017). 2016 Novel drugs summary. CDER, FDA Brochure, January 2017, pp-1-15.
Jarvis LM (2016). The Year in New Drugs. Chemical & Engineering News 94(5): 12-17.
Reddy DS (2012). Novel new drug approvals in 2011: A succinct analysis of drug discovery trends in the United States. Int J Pharm Sci Nanotech 5(2): 1661-1665.
Reddy DS (2013). New drugs of 2012: A concise overview of the NMEs and trends for innovative brand market in the United States. Int J Pharm Sci Nanotech 6(2): 2009-2013.
Reddy DS (2014). An overview of novel drugs and new chemical entities in 2013. Int J Pharm Sci Nantotech 7(3): 2505-2508.
Reddy SM and Reddy DS (2015). The novel drugs of 2014: Record approvals for niche markets. Int J Pharm Sci Nantotech 8(3): 2889-2893.
Reddy DS and Reddy SM (2016). The Novel Drugs of 2015 – An extraordinary growth of innovative pharmaceuticals. Int J Pharm Sci Nanotech 9(4): 3337-3344.
Reddy DS and Woodward R (2004). Ganaxolone: A perspective overview. Drugs Future 29: 227-242.
Scannell JW, Blanckley A, Helen Boldon H, and Warrington B (2012). Diagnosing the decline in pharmaceutical R & D efficiency. Nature Rev Drug Discovery 11: 191-200.
Mullard A (2016). 2015 FDA drug approvals. Nature Reviews Drug Discovery 15: 73-76.

Most read articles by the same author(s)

1 2 > >>